• Satsuma Pharmaceuticals Gains US FDA Approval for Atzumi Nasal Powder for Migraines marketscreener.com Fri, 02 May 2025 01:32:41 GMT
• fda approves atzumi, nasal powder formulation of dhe, for acute treatment of migraine Pharmacy Times Thu, 01 May 2025 19:51:14 GMT
• Durham firm wins approval for new migraine treatment The Business Journals Thu, 01 May 2025 19:30:00 GMT
• Satsuma's nasal powder rebounds from rejection to clinch FDA approval for migraine FirstWord Pharma Thu, 01 May 2025 19:10:25 GMT
• FDA Approves STS101 (Dihydroergotamine) Nasal Powder for Acute Treatment of Migraine Patient Care Online Thu, 01 May 2025 17:26:15 GMT
• FDA approves Satsuma’s migraine nasal spray after rejection in 2024 Endpoints News Thu, 01 May 2025 14:55:00 GMT
• fda approves sts101 nasal powder as new treatment for acute migraine Neurology live Thu, 01 May 2025 13:36:26 GMT
• Satsuma Pharmaceuticals Gains FDA Approval for Migraine Treatment TipRanks Thu, 01 May 2025 03:23:36 GMT
• Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migrai... PR Newswire Thu, 01 May 2025 00:00:00 GMT
• Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi? (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migrai... marketscreener.com Wed, 30 Apr 2025 22:00:00 GMT
• fda delays pdufa date for small biotech, raising questions about impact of agency cuts Endpoints News Tue, 29 Apr 2025 10:00:00 GMT
• endo signs agreements to sell international pharmaceuticals business for $6.1b Citizen Matters Fri, 25 Apr 2025 20:56:24 GMT
• migraine clinical trials and studies 2025: ema, pdma, fda approvals, mechanism of action, roa, nda, ind, and companies The Globe and Mail Wed, 23 Apr 2025 21:56:00 GMT
• expanding access to whole genome sequencing in parkinson research: james beck, phd Neurology live Thu, 17 Apr 2025 07:00:00 GMT
• improving timely als diagnosis with the thinkals toolkit: melody schaeffer, phd, mph Neurology live Mon, 14 Apr 2025 07:00:00 GMT
• global acute migraine treatment market to reach $4.44 billion by 2029 with a growth rate of 11.2% as reveal... WhaTech Tue, 11 Mar 2025 06:59:48 GMT
• non-postoperative acute pain drugs market 2034: ema, pdma, fda openPR Mon, 17 Feb 2025 08:00:00 GMT
• fda approves apomorphine infusion device spn-830 as new parkinson treatment Neurology live Tue, 04 Feb 2025 08:00:00 GMT
• fda approves vertex pharmaceuticals' suzetrigine for acute pain management Neurology live Thu, 30 Jan 2025 08:00:00 GMT
• feasibility and scalability of amprion’s assay for synucleinopathy diagnosis: russ lebovitz, md, phd Neurology Live Fri, 24 Jan 2025 18:11:15 GMT
• migraine pipeline 2024: key developments, emerging therapies, openPR Fri, 24 Jan 2025 15:44:00 GMT
• pending fda decisions in neurology to watch in the first half of 2025 Neurology Live Thu, 23 Jan 2025 09:12:17 GMT
• establishing entrustable professional activities for neurocritical care apps: daniel harrison, md Neurology Live Wed, 22 Jan 2025 23:17:51 GMT
• improving ms management through early intervention and precision medicine: emilio portaccio, md Neurology Live Wed, 22 Jan 2025 18:05:10 GMT
• pending fda decisions in neurology to watch in the first half of 2025 Neurology live Wed, 22 Jan 2025 08:00:00 GMT
• 12 facts on wildfire smoke: short- and long-term effects on human health and the environment Patient Care Online Mon, 13 Jan 2025 08:00:00 GMT
• neurologylive® year in review 2024: top stories in movement disorders Neurology Live Sun, 29 Dec 2024 10:17:19 GMT
• neurologylive® year in review 2024: top stories in headache and migraine Neurology live Sat, 28 Dec 2024 08:00:00 GMT
• fda tracker: 2024 ends with lilly’s landmark glp-1 sleep apnea approval BioSpace Tue, 24 Dec 2024 08:00:00 GMT
• fda tracker: fda hands out atopic dermatitis approvals to galderma, organon BioSpace Wed, 18 Dec 2024 04:17:22 GMT
• anti-migraine medications safety during pregnancy in the us Frontiers Tue, 17 Dec 2024 08:00:00 GMT
• anti-migraine medications safety during pregnancy in the us Frontiers Mon, 16 Dec 2024 08:00:00 GMT
• satsuma’s nda filing after cmc woes; hovione’s irish and us expansion Endpoints News Wed, 27 Nov 2024 08:00:00 GMT
• satsuma pharmaceuticals, inc. and shin nippon biomedical laboratories, ltd. receive fda acceptance of nda resubmission of sts101 f... Marketscreener.com Tue, 26 Nov 2024 17:12:06 GMT
• Satsuma Pharmaceuticals and SNBL Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine With or ... PR Newswire Tue, 26 Nov 2024 08:00:00 GMT
• transmucosal drug delivery devices global market report 2024-2033: size, share, growth & trends WhaTech Mon, 25 Nov 2024 11:42:12 GMT
• amneal files again for fda approval of first dihydroergotamine autoinjector Pharmaceutical Technology Fri, 22 Nov 2024 08:00:00 GMT
• non-postoperative acute pain treatment market 2034: clinical trials, medication, prevalence, incidence, therapies, ema, pdma, fda ... Barchart Thu, 21 Nov 2024 08:00:00 GMT
• using data collection to improve parkinson disease treatment personalization: amanda hare, dnp Neurology Live Thu, 14 Nov 2024 08:00:00 GMT
• After setback, Durham pharma tries again for FDA approval The Business Journals Fri, 01 Nov 2024 07:00:00 GMT
• acumen pharmaceuticals’ phase 2 advancements in alzheimer disease screening: todd feaster, psyd Neurology live Fri, 01 Nov 2024 07:00:00 GMT
• innovative launch at 2024 jeddah international motor show: presenting baic's bj30 and bj60 The Malaysian Reserve Thu, 31 Oct 2024 01:17:06 GMT
• chesapeake utilities corporation completes commissioning of full circle dairy renewable natural gas facility in florida The Malaysian Reserve Thu, 31 Oct 2024 01:16:53 GMT
• satsuma pharmaceuticals, inc. resubmits new drug application for sts101 for acute treatment of migraine with or without aura Marketscreener.com Wed, 30 Oct 2024 23:30:00 GMT
• health beat: beating the odds in fighting kidney cancer 69News WFMZ-TV Wed, 30 Oct 2024 20:00:00 GMT
• neurovoices: john winkelman, md, phd, on taking a major shift away from dopamine agonists in the revised guidelines for restless l... Neurology live Wed, 16 Oct 2024 07:00:00 GMT
• women with little to no migraine disability had a lower quality of life than men MD Magazine Mon, 14 Oct 2024 20:02:42 GMT
• phase 3 data supports the long-term safety of sts101 for acute treatment of migraine MD Magazine Mon, 14 Oct 2024 12:04:02 GMT
• adult-onset sma: diagnosis and best practices for clinicians Neurology Live Sun, 13 Oct 2024 07:00:00 GMT
• satsuma pharmaceuticals and snbl announce publication of sts101 (dihydroergotamine nasal powder) pivotal phase 3 ascend study in c... Yahoo Finance Tue, 08 Oct 2024 07:00:00 GMT
• new breakthrough study of bmb-101, positive phase 1 data on orexin agonist orx750, dosing commenced for qrl-101 Neurology live Sat, 21 Sep 2024 07:00:00 GMT
• expert discusses pharmacy deserts, expanding pharmacy access Pharmacy Times Thu, 19 Sep 2024 07:00:00 GMT
• acute migraine treatment market segments, drivers, restraints, and trends for 2024-2033 EIN News Tue, 17 Sep 2024 14:45:00 GMT
• 7mm migraine drug market forecast and analysis to 2033: focus on us, france, germany, italy, spain, the uk, and japan 24matins.uk Fri, 13 Sep 2024 10:49:29 GMT
• Rivus Pharmaceuticals Strengthens Executive Team and Board with Appointments of Tom O'Neil as Chief Financial Officer and Erin Lav... PR Newswire Wed, 11 Sep 2024 07:00:00 GMT
• rivus pharmaceuticals appoints tom o'neil as chief financial officer and erin lavelle as director citybiz Wed, 11 Sep 2024 07:00:00 GMT
• acute migraine treatment market innovations investigated by report, size, share, growth, trends, competitiv... WhaTech Mon, 09 Sep 2024 09:55:11 GMT
• importance of multidisciplinary care in management of neurofibromatosis type 1 related plexiform neurofibroma Neurology Live Tue, 13 Aug 2024 07:00:00 GMT
• fda decision tracker: ars wins approval for first epinephrine nasal spray BioSpace Fri, 09 Aug 2024 07:00:00 GMT
• current and emerging treatment options for neurofibromatosis type 1 related plexiform neurofibroma Neurology Live Tue, 06 Aug 2024 07:00:00 GMT
• fda approves first engineered t cell therapy for solid tumors, expands gsk’s jemperli BioSpace Tue, 06 Aug 2024 07:00:00 GMT
• future challenges for neurology departments and neurology educators Neurology Live Thu, 01 Aug 2024 07:00:00 GMT
• fda decision tracker: j&j scores new approval for multiple myeloma therapy BioSpace Wed, 31 Jul 2024 07:00:00 GMT
• transition of care for neurofibromatosis type 1 related plexiform neurofibroma from adolescent to adulthood Neurology Live Tue, 30 Jul 2024 07:00:00 GMT
• m&a activity – fuelling innovation in hard-to-treat cns disorders The Pharma Letter Fri, 26 Jul 2024 07:00:00 GMT
• singapore’s sats inks food venture with japan’s mitsui just-food.com Fri, 19 Jul 2024 07:00:00 GMT
• fda rejects orexo’s opioid overdose drug, grants third indication for phathom’s voquezna BioSpace Fri, 19 Jul 2024 07:00:00 GMT
• slideshow: pharmacists report burnout is a major driver of understaffing in pharmacy times survey Pharmacy Times Tue, 16 Jul 2024 07:00:00 GMT
• fda rejects orexo’s opioid overdose drug, grants third indication for phathom’s voquezna BioSpace Tue, 16 Jul 2024 07:00:00 GMT
• fda tracker: zealand’s glp-2 drug rejected while xcovery wins first approval, targets nsclc BioSpace Mon, 15 Jul 2024 11:09:52 GMT
• fda decision tracker: ars wins approval for first epinephrine nasal spray BioSpace Mon, 15 Jul 2024 11:09:52 GMT
• fda approves first engineered t cell therapy for solid tumors, expands gsk’s jemperli BioSpace Mon, 15 Jul 2024 11:09:52 GMT
• fda decision tracker: sun pharma scores approval for severe alopecia areata treatment BioSpace Mon, 15 Jul 2024 11:09:52 GMT
• fda greenlights sun pharma’s severe alopecia areata treatment BioSpace Mon, 15 Jul 2024 11:09:52 GMT
• fda rejects orexo’s opioid overdose drug, grants third indication for phathom’s voquezna BioSpace Mon, 15 Jul 2024 11:09:52 GMT
• fda decision tracker: novo’s once-weekly insulin icodec rejected BioSpace Fri, 12 Jul 2024 07:00:00 GMT
• biopharma layoff tracker 2024: spark, novartis, indivior and more cut staff BioSpace Fri, 12 Jul 2024 07:00:00 GMT
• fda decision tracker: arcutis wins third indication in two years for zoryve BioSpace Fri, 12 Jul 2024 05:46:14 GMT
• fda decision tracker: arcutis wins third indication in two years for zoryve BioSpace Thu, 11 Jul 2024 07:00:00 GMT
• fda decision tracker: lilly’s kisunla gets greenlight to compete with leqembi BioSpace Thu, 04 Jul 2024 05:50:38 GMT
• fda decision tracker: lilly’s kisunla gets greenlight to compete with leqembi BioSpace Wed, 03 Jul 2024 07:00:00 GMT
• biopharma layoff tracker 2024: apollomics, curevac, takeda and more cut staff BioSpace Wed, 03 Jul 2024 07:00:00 GMT
• treatments approved for treatment of spinal muscular atrophy Neurology Live Mon, 01 Jul 2024 07:00:00 GMT
• fda decision tracker: fda issues crl for rocket’s gene therapy BioSpace Mon, 01 Jul 2024 07:00:00 GMT
• Satsuma Pharmaceuticals | Biotechnology | The Pharmaletter The Pharma Letter Mon, 01 Jul 2024 01:19:25 GMT
• intersect ent announces changes to its board of directors Quantisnow Sun, 30 Jun 2024 08:03:15 GMT
• satsuma pharmaceuticals shares are trading higher after the company announced that it entered a definitive ... Quantisnow Sun, 30 Jun 2024 00:02:22 GMT
• fda denies merck, daiichi sankyo in nsclc; approves new copd, lymphoma drugs BioSpace Sat, 29 Jun 2024 10:18:47 GMT
• fda denies merck, daiichi sankyo in nsclc; approves new copd, lymphoma drugs BioSpace Fri, 28 Jun 2024 19:52:30 GMT
• fda decision tracker: second bust for abbvie parkinson’s treatment BioSpace Wed, 26 Jun 2024 07:00:00 GMT
• satsuma pharmaceuticals and snbl announce five abstracts on sts101 for the acute treatment of migraine to be ... Longview News-Journal Tue, 25 Jun 2024 15:20:57 GMT
• bms, argenx win new indications for krazati, vyvgart hytrulo BioSpace Tue, 25 Jun 2024 10:11:18 GMT
• investigational nasal powder rapidly, effectively cuts migraine pain Medscape Tue, 25 Jun 2024 07:00:00 GMT
• dihydroergotamine led to significant headache pain reduction at 48 hours, up to 12 months Healio Mon, 24 Jun 2024 07:00:00 GMT
• bms, argenx win new indications for krazati, vyvgart hytrulo BioSpace Mon, 24 Jun 2024 07:00:00 GMT
• bellerophon (blph) receives fda acceptance to reduce study size Yahoo New Zealand News Fri, 21 Jun 2024 16:55:41 GMT
• abbvie, merck rack up approvals in uc, endometrial cancer and pneumonia BioSpace Fri, 21 Jun 2024 09:58:21 GMT
• biopharma layoff tracker 2024: ginkgo, cara, barinthus and more cut staff BioSpace Fri, 21 Jun 2024 07:00:00 GMT
• abbvie, merck rack up approvals in uc, endometrial cancer and pneumonia BioSpace Thu, 20 Jun 2024 07:00:00 GMT
• wave therapeutics (wve) up on update from huntington's study Yahoo Movies Canada Wed, 19 Jun 2024 04:27:49 GMT
• 9 meters (nmtr) up on results from bowel syndrome candidate Yahoo News Malaysia Mon, 17 Jun 2024 18:44:53 GMT
• bellerophon (blph) receives fda acceptance to reduce study size Yahoo New Zealand News Mon, 17 Jun 2024 09:00:00 GMT
• astrazeneca, amgen and bms add new indications for cancer drugs BioSpace Mon, 17 Jun 2024 07:00:00 GMT
• cyrano therapeutics announces the appointment of john kollins to its board of directors Quantisnow Sat, 15 Jun 2024 20:35:41 GMT
• ai-based models accurately predict, show promise for expansion in headache Healio Fri, 14 Jun 2024 07:00:00 GMT
• promising developments in pharmaceutical treatments for sleep apnea: sanjay r. patel, md, ms Neurology live Thu, 13 Jun 2024 07:00:00 GMT
• satsuma pharmaceuticals and snbl announce five abstracts on sts101 for the acute treatment of migraine to be presented at the amer... PR Newswire Thu, 13 Jun 2024 07:00:00 GMT
• fda greenlights first drug in nearly a decade for rare liver disease BioSpace Tue, 11 Jun 2024 07:00:00 GMT
• biopharma layoff tracker 2024: bms, takeda, evotec and more cut staff BioSpace Thu, 06 Jun 2024 07:00:00 GMT
• here's why we're watching satsuma pharmaceuticals' (nasdaq:stsa) cash burn situation Yahoo Canada Shine On Wed, 05 Jun 2024 01:21:00 GMT
• fda approves lilly’s retevmo for pediatric indications, non-stimulant adhd drug BioSpace Thu, 30 May 2024 14:40:07 GMT
• fda grants approval for first biosimilar to astrazeneca’s soliris BioSpace Thu, 30 May 2024 00:56:31 GMT
• what type of shareholders make up satsuma pharmaceuticals, inc.'s (nasdaq:stsa) share registry? Yahoo News Australia Wed, 29 May 2024 04:25:00 GMT
• does satsuma pharmaceuticals (stsa) have the potential to rally 90% as wall street analysts expect? Yahoo Canada Shine On Tue, 28 May 2024 12:13:57 GMT
• are institutions heavily invested in satsuma pharmaceuticals, inc.'s (nasdaq:stsa) shares? Yahoo Movies UK Mon, 27 May 2024 13:39:20 GMT
• what type of shareholders make up satsuma pharmaceuticals, inc.'s (nasdaq:stsa) share registry? Yahoo News Australia Sun, 26 May 2024 10:16:02 GMT
• are institutions heavily invested in satsuma pharmaceuticals, inc.'s (nasdaq:stsa) shares? Yahoo Movies UK Sat, 25 May 2024 12:49:58 GMT
• what type of shareholders make up satsuma pharmaceuticals, inc.'s (nasdaq:stsa) share registry? Yahoo News Australia Fri, 24 May 2024 01:58:52 GMT
• biopharma layoff tracker 2024: erasca, bolt, tenaya and more cut staff BioSpace Fri, 17 May 2024 16:27:06 GMT
• amgen’s imdelltra becomes first bi-specific t-cell engager for advanced sclc BioSpace Fri, 17 May 2024 07:00:00 GMT
• bms’s breyanzi secures fourth fda approval, for follicular lymphoma BioSpace Fri, 17 May 2024 03:47:08 GMT
• bms’s breyanzi secures fourth fda approval, for follicular lymphoma BioSpace Thu, 16 May 2024 19:47:35 GMT
• aacr annual meeting 2018 - analgesia, dihydroergotamine The Pharma Letter Thu, 16 May 2024 08:40:46 GMT
• dynavax technologies’ hepatitis b vaccine turned down for hemodialysis patients BioSpace Wed, 15 May 2024 09:43:19 GMT
• dynavax technologies’ hepatitis b vaccine turned down for hemodialysis patients BioSpace Tue, 14 May 2024 07:00:00 GMT
• what kind of investors own most of satsuma pharmaceuticals, inc. (nasdaq:stsa)? Yahoo Canada Shine On Wed, 08 May 2024 17:21:43 GMT
• biopharma layoff tracker 2024: marinus, kenvue, emergent and more cut staff BioSpace Wed, 08 May 2024 07:00:00 GMT
Satsuma Pharmaceuticals, Inc(NASDAQ:STSA) 
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in AS...
Website: http://www.satsumarx.com
Founded: 2016
IPO Price: $15 (Sep 13, 2019)
Full Time Employees: 17
CEO: John A. Kollins
Sector: Healthcare
Industry: Biotechnology